<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Hypertrophic Cardiomyopathy - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "‚Ü≥ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Hypertrophic Cardiomyopathy</span>
        </nav>

        <header class="page-header">
            <h1>Hypertrophic Cardiomyopathy</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Complex</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0005045" target="_blank">
                        MONDO:0005045
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Cardiovascular Disease</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Genetic Disorder</span>
                
            </div>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">11</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">cardiovascular disorder</span>
                    
                    <span class="tag tag-classification">cardiomyopathy</span>
                    
                    <span class="tag tag-classification">hereditary disease</span>
                    
                </div>
            </div>
            
            
            
            
            
            
        </div>
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">2</span>
            </div>
            
            
            
                
                
                    
                
                
            
                
                
                
            
            
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Obstructive HCM
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">The thickened heart muscle obstructs blood flow out of the left ventricle.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38368032" target="_blank">PMID:38368032</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Obstruction to left ventricular outflow occurs in approximately 60% of patients."</div>
                
                
                <div class="evidence-explanation">The provided literature states that obstruction occurs in approximately 60% of HCM patients, indicating that not all HCM cases are obstructive. Thus, the statement that the thickened heart muscle obstructs blood flow out of the left ventricle can be recognized as a subtype known as obstructive HCM but does not apply to all HCM patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35555885" target="_blank">PMID:35555885</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Left ventricular (LV) wall thickening, or LV hypertrophy (LVH), is common and occurs in diverse conditions including hypertrophic cardiomyopathy (HCM)..."</div>
                
                
                <div class="evidence-explanation">The literature indicates that LV hypertrophy (LVH) occurs in HCM alongside various conditions. However, it characterizes different forms, not solely obstructive HCM, thereby acknowledging the partial correctness of the subtype Obstructive HCM but not exclusively.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20560010" target="_blank">PMID:20560010</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Left ventricular outflow tract obstruction (LVOTO) is one of the defining features of hypertrophic cardiomyopathy (HCM)..."</div>
                
                
                <div class="evidence-explanation">This specific literature confirms that left ventricular outflow tract obstruction (LVOTO) is a defining feature of HCM, thereby supporting the statement regarding the thickened heart muscle obstructing blood flow out of the left ventricle.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Non-Obstructive HCM
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">The heart muscle is thickened, but blood flow is not significantly obstructed.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34126727" target="_blank">PMID:34126727</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Patients with non-obstructive HCM... According to the characteristics of cardiac morphology and function shown by echocardiography, the patients were divided into common type, dilated type, restricted type and reduced ejection fraction type."</div>
                
                
                <div class="evidence-explanation">The reference describes non-obstructive hypertrophic cardiomyopathy (HCM) as a subtype of HCM characterized by different clinical subtypes based on cardiac morphology and function, supporting the statement that non-obstructive HCM involves thickened heart muscle without significant obstruction of blood flow.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35555885" target="_blank">PMID:35555885</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Left ventricular (LV) wall thickening, or LV hypertrophy (LVH), is common and occurs in diverse conditions including hypertrophic cardiomyopathy (HCM)...Although various diseases share LV wall thickening as a common feature, the histologic changes that underscore each disease are distinct."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by acknowledging that hypertrophic cardiomyopathy can include conditions with thickened heart muscle where the histological features differ, indicating diverse subtypes including non-obstructive forms.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Sarcomere Protein Mutations</div>
                
                <div class="item-desc">Genetic mutations affecting the proteins of the cardiac sarcomere lead to abnormal thickening of the heart muscle. The central biophysical abnormality is sarcomere hypercontractility with increased myosin duty ratio and power, resulting in impaired relaxation and elevated energetic cost of contraction.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Cardiomyocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000746" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        muscle contraction
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006936" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        regulation of heart contraction
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0008016" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        ATP hydrolysis activity
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0016887" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-component">
                        sarcomere
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030017" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-component">
                        thick filament
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005863" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-component">
                        thin filament
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005865" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        left ventricle
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002084" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        interventricular septum
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002094" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16416046" target="_blank">PMID:16416046</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hypertrophic Cardiomyopathy (HCM) is a relatively common primary cardiac disorder defined as the presence of a hypertrophied left ventricle... to date, 270 independent mutations in nine sarcomeric protein genes have been linked to Familial Hypertrophic Cardiomyopathy (FHC)..."</div>
                
                
                <div class="evidence-explanation">The reference discusses how mutations in sarcomeric protein genes are linked to hypertrophic cardiomyopathy, which leads to heart muscle thickening.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36797478" target="_blank">PMID:36797478</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The most common form of genetic heart disease is hypertrophic cardiomyopathy (HCM), which is caused by variants in cardiac sarcomeric genes and leads to abnormal heart muscle thickening."</div>
                
                
                <div class="evidence-explanation">This reference directly states that HCM is caused by variants in sarcomeric genes resulting in heart muscle thickening.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28645928" target="_blank">PMID:28645928</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"For example, increased myosin heavy chain (MHC) binding and ATP utilization lead to the hypercontractile sarcomere in HCM..."</div>
                
                
                <div class="evidence-explanation">This reference explains how specific mutations in sarcomeric proteins lead to hypercontractility, a feature of muscle thickening in HCM.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Myocyte Disarray</div>
                
                <div class="item-desc">Disorganization of heart muscle cells contributes to the stiffness and dysfunction of the myocardium. Loss of physiological fiber alignment and orientation creates structural abnormalities that impair contractile efficiency and promote arrhythmogenic substrate.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Cardiomyocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000746" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        ventricular myocardium
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002084" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33447843" target="_blank">PMID:33447843</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Myocardial disarray is defined as disorganized cardiomyocyte spatial distribution, with loss of physiological fibre alignment and orientation."</div>
                
                
                <div class="evidence-explanation">The paper discusses how myocardial disarray is a typical feature of hypertrophic cardiomyopathy (HCM), implying its role in myocardial dysfunction.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/7665141" target="_blank">PMID:7665141</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Genes on five loci on separate chromosomes are responsible for a familial disease in which all or part of the ventricular muscle undergoes thickening with a histological picture of irregular hypertrophy and disorganized arrangement of myocytes (disarray)."</div>
                
                
                <div class="evidence-explanation">This indicates that myocyte disarray is a feature of the disease, contributing to the thickening and impaired function of the myocardium.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11040002" target="_blank">PMID:11040002</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Within an individual heart the magnitude of hypertrophy correlated with the severity of fibrosis (p = 0.006) and disarray (p = 0.0002)."</div>
                
                
                <div class="evidence-explanation">The correlation between hypertrophy, fibrosis, and disarray supports the statement that myocyte disarray contributes to myocardial dysfunction.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Myocardial Fibrosis</div>
                
                <div class="item-desc">Increased collagen deposition by interstitial cells contributes to myocardial stiffness. Activation of TGF-beta and MAPK signaling pathways promotes extracellular matrix remodeling and fibrosis, which is a progressive phenomenon associated with greater disease severity.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Interstitial Cells
                        
                        <a href="http://purl.obolibrary.org/obo/CL_4030031" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        cardiac fibroblast
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0002548" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        extracellular matrix organization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030198" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        response to TGF-beta
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0071559" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-component">
                        extracellular matrix
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0031012" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        myocardial interstitium
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002084" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/1414892" target="_blank">PMID:1414892</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"It appears that increased collagen production is mainly responsible for the functional consequences of structural remodelling"</div>
                
                
                <div class="evidence-explanation">The increased collagen production discussed here is consistent with the contribution of interstitial cells to myocardial stiffness.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25573453" target="_blank">PMID:25573453</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Tissue from cats with pre-clinical HCM also had a higher number of neutrophils and a greater collagen content than the myocardium of normal cats."</div>
                
                
                <div class="evidence-explanation">This study shows increased collagen deposition, contributing to myocardial stiffness, aligning with the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29522370" target="_blank">PMID:29522370</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We conclude that myocardial macrophages play an important role in the time-dependent increases in SPARC that enhance postsynthetic collagen processing, insoluble collagen content, and myocardial stiffness and contribute to the development of fibrosis."</div>
                
                
                <div class="evidence-explanation">The role of interstitial cells like macrophages in increasing collagen content supports the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Altered Calcium Handling</div>
                
                <div class="item-desc">Increased myofilament calcium sensitivity and impaired diastolic calcium removal lead to diastolic dysfunction and promote pro-hypertrophic signaling. Altered calcium homeostasis contributes to both contractile abnormalities and arrhythmogenic substrate.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Cardiomyocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000746" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        calcium ion transport
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006816" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        regulation of cardiac muscle contraction
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0055117" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-component">
                        sarcoplasmic reticulum
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0016529" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        left ventricle
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002084" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Mitochondrial Dysfunction</div>
                
                <div class="item-desc">Elevated energetic cost of sarcomere hypercontractility leads to mitochondrial stress and downregulation of energy metabolism pathways. Impaired ATP production contributes to contractile dysfunction and cellular remodeling.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Cardiomyocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000746" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        ATP metabolic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0046034" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        oxidative phosphorylation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006119" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-component">
                        mitochondrion
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005739" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        myocardium
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002084" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Left Ventricular Outflow Tract Obstruction</div>
                
                <div class="item-desc">Asymmetric septal hypertrophy combined with systolic anterior motion of the mitral valve creates dynamic obstruction to blood flow. Venturi forces draw the mitral valve toward the septum, elevating wall stress and contributing to ischemia and further hypertrophic remodeling.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Cardiomyocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000746" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        interventricular septum
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002094" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        mitral valve
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002135" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        left ventricular outflow tract
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0016480" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    Arrhythmias[&#34;Arrhythmias&#34;]
    Sudden_Cardiac_Death[&#34;Sudden Cardiac Death&#34;]
    Palpitations[&#34;Palpitations&#34;]

    Arrhythmias --&gt; Palpitations
    Arrhythmias --&gt; Sudden_Cardiac_Death

    style Arrhythmias fill:#fef3c7
    style Sudden_Cardiac_Death fill:#fef3c7
    style Palpitations fill:#fef3c7</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">11</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Cardiovascular<span class="pill-count">(7)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Respiratory<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Constitutional<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-4">Other<span class="pill-count">(1)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Cardiovascular
                    <span class="cat-count">7</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Syncope
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001279" target="_blank">
                                Syncope
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001279)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Often triggered by exertion</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29150126" target="_blank">PMID:29150126</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Clinical manifestations of Hypertrophic Cardiomyopathy include shortness of breath, chest pain, palpitations and syncope, which are related to the onset of diastolic dysfunction, left ventricular outflow tract obstruction, ischemia, atrial fibrillation and abnormal vascular responses."</div>
                
                
                <div class="evidence-explanation">The excerpt directly states that syncope is a clinical manifestation of hypertrophic cardiomyopathy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36442670" target="_blank">PMID:36442670</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Syncope in hypertrophic cardiomyopathy: Explaining the unexplained."</div>
                
                
                <div class="evidence-explanation">Syncope is highlighted as a phenomenon occurring in individuals with hypertrophic cardiomyopathy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29761339" target="_blank">PMID:29761339</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Syncope and presyncope-in addition to extremely variable cardiac symptoms (dyspnea and angina)-are common."</div>
                
                
                <div class="evidence-explanation">The text explicitly mentions syncope as a common symptom in hypertrophic cardiomyopathy patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Arrhythmias
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0011675" target="_blank">
                                Arrhythmia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0011675)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34969871" target="_blank">PMID:34969871</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Study aims were to estimate the population-diagnosed prevalence of cardiomyopathies and describe the temporal relationship between a diagnosis of cardiomyopathy with HF and arrhythmia... Between 2010 and 2018, prevalence increased for ARVC by 180% and HCM by 9%."</div>
                
                
                <div class="evidence-explanation">The study indicates a relationship between hypertrophic cardiomyopathy (HCM) and arrhythmias, supporting the statement that arrhythmias are a common cardiovascular phenotype of HCM.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/7201843" target="_blank">PMID:7201843</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The patients with hypertrophic cardiomyopathy showed a significant increase in supraventricular extrasystoles/24 hours, supraventricular arrhythmias, high grade ventricular arrhythmia, and the number of patients with more than 10 ventricular extrasystoles every 24 hours when compared with the..."</div>
                
                
                <div class="evidence-explanation">This study directly assesses the prevalence and types of arrhythmias in patients with hypertrophic cardiomyopathy, confirming that arrhythmias are a common phenotype.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/3158692" target="_blank">PMID:3158692</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Frequent ventricular premature complexes, complex ventricular ectopic activity and asymptomatic ventricular tachycardia are common to both hypertrophic and dilated cardiomyopathy; in both conditions, sudden death is a common occurrence."</div>
                
                
                <div class="evidence-explanation">This reference mentions common arrhythmic events in hypertrophic cardiomyopathy, supporting the idea that arrhythmias are a common cardiovascular phenotype in HCM.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Arrhythmias
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0011675" target="_blank">
                                Arrhythmia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0011675)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Abnormal heart rhythms are common. Can include atrial fibrillation and ventricular arrhythmias.</div>
                    
                    
                    <div class="item-meta">
                        <strong style="font-size: 0.8rem; color: #166534;">Sequelae:</strong>
                        
                        <span class="tag" style="background: #bbf7d0; color: #166534;">Palpitations</span>
                        
                        <span class="tag" style="background: #bbf7d0; color: #166534;">Sudden Cardiac Death</span>
                        
                    </div>
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23124402" target="_blank">PMID:23124402</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hypertrophic cardiomyopathy is the most common genetic cardiovascular disorder and the leading cause of sudden cardiac death in the young. This article reviews the ventricular arrhythmias associated with hypertrophic cardiomyopathy."</div>
                
                
                <div class="evidence-explanation">The reference confirms that hypertrophic cardiomyopathy is associated with ventricular arrhythmias and is a leading cause of sudden cardiac death.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28602671" target="_blank">PMID:28602671</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Patients with HCM are predisposed to developing atrial fibrillation (AF) due primarily to advanced diastolic dysfunction and left atrial (LA) dilatation and remodelling."</div>
                
                
                <div class="evidence-explanation">The reference confirms that atrial fibrillation is common in patients with hypertrophic cardiomyopathy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29203161" target="_blank">PMID:29203161</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Cardiac arrhythmias refer to any abnormality or disturbance in the normal activation sequence of the myocardium and may be indicative of structural heart disease and the cause of significant cardiovascular complications and sudden cardiac death."</div>
                
                
                <div class="evidence-explanation">The reference discusses the role of arrhythmias in structural heart disease, including hypertrophic cardiomyopathy, and their association with significant cardiovascular complications and sudden cardiac death.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Palpitations
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001962" target="_blank">
                                Palpitations
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001962)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Often associated with atrial fibrillation and ventricular arrhythmias</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Sudden Cardiac Death
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001645" target="_blank">
                                Sudden cardiac death
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001645)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Highest risk in young patients and those with sarcomere-positive disease. Leading cause of sudden death in young athletes.</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Left Ventricular Hypertrophy
                        
                        <span class="phenotype-freq">OBLIGATE</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001712" target="_blank">
                                Left ventricular hypertrophy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001712)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Defining feature of HCM; often asymmetric with septal predominance</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Atrial Fibrillation
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0005110" target="_blank">
                                Atrial fibrillation
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0005110)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Due to advanced diastolic dysfunction and left atrial dilatation and remodeling. Genotype-positive status associated with higher lifetime hazard.</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Respiratory
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Dyspnea
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002094" target="_blank">
                                Dyspnea
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002094)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29655822" target="_blank">PMID:29655822</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Heart failure (HF), characterized by excessive exertional dyspnea, is a common complication within the broad clinical spectrum of hypertrophic cardiomyopathy (HCM)."</div>
                
                
                <div class="evidence-explanation">The literature provided mentions that exertional dyspnea is common in patients with hypertrophic cardiomyopathy, supporting the statement that dyspnea is a common phenotype of HCM.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Constitutional
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Chest Pain
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0100749" target="_blank">
                                Chest pain
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0100749)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34533409" target="_blank">PMID:34533409</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hypertrophic cardiomyopathy (HCM) is a complex disease characterized by thickening of the cardiac muscle. Common symptoms include chest pain, shortness of breath, palpitations, fatigue and syncope (fainting), which are often confused for other conditions."</div>
                
                
                <div class="evidence-explanation">This literature supports the statement as it lists chest pain as a common symptom of Hypertrophic Cardiomyopathy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Fatigue
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0012378" target="_blank">
                                Fatigue
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0012378)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Due to reduced cardiac output and efficiency.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34533409" target="_blank">PMID:34533409</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Common symptoms include chest pain, shortness of breath, palpitations, fatigue and syncope (fainting)..."</div>
                
                
                <div class="evidence-explanation">The reference mentions fatigue as a common symptom of hypertrophic cardiomyopathy, supporting the statement that fatigue occurs occasionally in this condition.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37715354" target="_blank">PMID:37715354</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A 59-year-old man was referred for SSM as dyspnoea and low threshold muscle fatigue associated to severe left ventricular outflow obstruction..."</div>
                
                
                <div class="evidence-explanation">The reference describes a patient with hypertrophic obstructive cardiomyopathy experiencing muscle fatigue, aligning with the statement that fatigue is occasionally observed due to reduced cardiac output and efficiency.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-4">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Other
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Mitral Valve Regurgitation
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                    </div>
                    
                    <div class="item-desc">Thickened heart muscle can affect mitral valve function, causing leakage.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21909825" target="_blank">PMID:21909825</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Elongation and pathological thickening of the mitral valve (MV) is commonly seen in hypertrophic cardiomyopathy (HCM)... failure of either to optimally adapt in this setting can result in mitral regurgitation."</div>
                
                
                <div class="evidence-explanation">The reference discusses the common occurrence of mitral valve elongation and thickening in HCM, which can lead to mitral regurgitation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35644869" target="_blank">PMID:35644869</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"RESULTS: Significant (more than mild) MR was a significant univariate predictor of all the three LA strain values"</div>
                
                
                <div class="evidence-explanation">This study shows that mitral regurgitation (MR) is a significant factor in patients with hypertrophic cardiomyopathy (HCM), supporting the statement that thickened heart muscle can affect mitral valve function, causing leakage.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37563454" target="_blank">PMID:37563454</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"However, the interplay between these conditions is increasingly being recognized and they frequently coexist, as in the paradigmatic examples of dilated cardiomyopathy and hypertrophic cardiomyopathy, which are often complicated by the occurrence of mitral regurgitation."</div>
                
                
                <div class="evidence-explanation">The reference indicates that hypertrophic cardiomyopathy is often complicated by mitral regurgitation, supporting the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">7</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    MYH7
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (6 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38423942" target="_blank">PMID:38423942</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hypertrophic cardiomyopathy: New pathogenic variant in MYH7."</div>
                
                
                <div class="evidence-explanation">The title of the referenced article explicitly indicates the association of a pathogenic variant in MYH7 with hypertrophic cardiomyopathy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23905887" target="_blank">PMID:23905887</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Genetic mutations can be identified in approximately 60% of patients; these are commonest in genes that encode proteins of the cardiac sarcomere."</div>
                
                
                <div class="evidence-explanation">While the specific mutations in MYH7 are not detailed in this snippet, the article supports the general assertion that genetic mutations, particularly in sarcomeric genes like MYH7, are common in hypertrophic cardiomyopathy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31735781" target="_blank">PMID:31735781</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"By NGS, we determined that these subjects with HCM symptoms carried a missense heterozygous genetic mutation c.2632C&gt;A (p.V878L) in the myosin heavy chain 7 (MYH7) gene with an autosomal dominant pattern of inheritance."</div>
                
                
                <div class="evidence-explanation">The article details a specific pathogenic variant (p.V878L) in the MYH7 gene associated with hypertrophic cardiomyopathy.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 3 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    MYBPC3
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34180388" target="_blank">PMID:34180388</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The proband carries a novel heterozygous nonsense variant of MYBPC3:c.2731G &gt; T (p.E911X) ... suggesting the functional damages to the protein of MYBPC3."</div>
                
                
                <div class="evidence-explanation">The study identifies a novel pathogenic variant in MYBPC3 associated with hypertrophic cardiomyopathy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24240729" target="_blank">PMID:24240729</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The second wave started in 1995 by the discovery that mutations in the gene encoding cMyBP-C cause hypertrophic cardiomyopathy (HCM)."</div>
                
                
                <div class="evidence-explanation">This review discusses that mutations in MYBPC3 (which encodes cMyBP-C) cause HCM.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37409452" target="_blank">PMID:37409452</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The 2 sarcomere genes most commonly associated with hypertrophic cardiomyopathy (HCM), MYBPC3 (myosin-binding protein C3)..."</div>
                
                
                <div class="evidence-explanation">Study identifies MYBPC3 as a common gene associated with hypertrophic cardiomyopathy.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TNNT2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33588347" target="_blank">PMID:33588347</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Variants were identified and annotated using in silico tools, and further classified as pathogenic or benign according to the American College of Medical Genetics and Genomics guidelines. Variants with functional effects were identified...and TNNT2..."</div>
                
                
                <div class="evidence-explanation">The study identifies pathogenic variants in TNNT2 among patients with hypertrophic cardiomyopathy, supporting the genetic association.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/7665141" target="_blank">PMID:7665141</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Genes on five loci on separate chromosomes are responsible for a familial disease in which all or part of the ventricular muscle undergoes thickening with a histological picture of irregular hypertrophy and disorganized arrangement of myocytes (disarray). The three genes identified so far encode..."</div>
                
                
                <div class="evidence-explanation">The study reveals that the troponin T gene (TNNT2) is one of the implicated genes in hypertrophic cardiomyopathy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    ALPK3
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    FHOD3
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TRIM63
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    SVIL
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Beta Blockers
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000186" target="_blank">
                            MAXO:0000186
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Used to reduce heart rate and improve symptoms</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35450574" target="_blank">PMID:35450574</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Beta-Blockers and Exercise Hemodynamics in Hypertrophic Cardiomyopathy."</div>
                
                
                <div class="evidence-explanation">This reference discusses the use of beta-blockers in the context of hypertrophic cardiomyopathy, which supports the statement that beta-blockers are used to improve symptoms in this condition, though details on heart rate reduction specifically may be implied but not detailed.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21389910" target="_blank">PMID:21389910</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Throughout the years, numerous medical treatments have been used to achieve symptom control in these patients, and include medications such as beta-blockers, calcium channel blockers, amiodarone, disopyramide, and angiotensin receptor blockers."</div>
                
                
                <div class="evidence-explanation">The abstract directly mentions the use of beta-blockers to control symptoms in hypertrophic cardiomyopathy, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37850394" target="_blank">PMID:37850394</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"beta-Adrenergic receptor antagonists (beta-blockers) are the first-line therapy for HCM. However, beta-blockers commonly selected for this disease are often poorly tolerated in patients, where heart-rate reduction and noncardiac effects can lead to reduced cardiac output and fatigue."</div>
                
                
                <div class="evidence-explanation">This reference confirms that beta-blockers are a first-line therapy for hypertrophic cardiomyopathy and are used for heart rate reduction, supporting the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Calcium Channel Blockers
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000434" target="_blank">
                            MAXO:0000434
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Help to relax heart muscle and improve blood flow</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17162264" target="_blank">PMID:17162264</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"For symptomatic patients with non-obstructed disease medical treatment with calcium channel blockers and beta-blockers is aimed to improve heart failure symptoms, and ischemia. Verapamil is the most often used, with likely benefit of relieving ischemia."</div>
                
                
                <div class="evidence-explanation">The literature supports that calcium channel blockers are used to improve symptoms in hypertrophic cardiomyopathy patients, which implies relaxing the heart muscle and improving blood flow.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/3515244" target="_blank">PMID:3515244</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The three approved calcium-channel blockers--nifedipine, verapamil and diltiazem--have offered new treatments for angina."</div>
                
                
                <div class="evidence-explanation">Even though the focus is on angina, the acknowledged use of calcium channel blockers reinforces their role in cardiovascular conditions including HCM.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36044874" target="_blank">PMID:36044874</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"CCBs are effective antihypertensive drugs and a very good therapeutic option for HTN LVH as they can cause reverse LVH remodeling."</div>
                
                
                <div class="evidence-explanation">The review suggests the effectiveness of calcium channel blockers in treating hypertensive left ventricular hypertrophy (HTN LVH), indicating a role in remodeling heart muscle, which aligns with improving blood flow.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Septal Myectomy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000004" target="_blank">
                            MAXO:0000004
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Surgical removal of part of the thickened heart muscle</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38368037" target="_blank">PMID:38368037</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Septal myectomy is a well-established procedure for septal reduction in patients with obstructive hypertrophic cardiomyopathy (HCM) who have not responded to medical treatment."</div>
                
                
                <div class="evidence-explanation">The literature directly confirms that septal myectomy is used to surgically remove part of the thickened heart muscle in hypertrophic cardiomyopathy patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31280832" target="_blank">PMID:31280832</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Surgical myectomy was initially advocated only for patients with symptoms refractory to maximal tolerated medical therapy."</div>
                
                
                <div class="evidence-explanation">This supports the usage of septal myectomy for removing thickened muscle parts as a treatment for hypertrophic cardiomyopathy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22687587" target="_blank">PMID:22687587</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Treatments for hypertrophic cardiomyopathy are largely selected based on patient symptoms and echocardiographic findings."</div>
                
                
                <div class="evidence-explanation">While this reference does not directly state septal myectomy, it mentions treatment selection based on symptoms, which aligns with the usage context of septal myectomy in other literature. Therefore, it indirectly supports the use.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Alcohol Septal Ablation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000004" target="_blank">
                            MAXO:0000004
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Minimally invasive procedure to reduce obstruction by injecting alcohol into a small artery that supplies the thickened heart muscle</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35710280" target="_blank">PMID:35710280</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Over the past several decades, alcohol septal ablation has become an established therapy for selected patients, in whom there is clinical improvement in symptoms as well as objective functional capacity."</div>
                
                
                <div class="evidence-explanation">This reference supports the use of alcohol septal ablation as a treatment for hypertrophic cardiomyopathy by describing improved clinical outcomes and functional capacity.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36598161" target="_blank">PMID:36598161</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"There are several invasive therapies including proven therapies such as alcohol septal ablation and septal myectomy."</div>
                
                
                <div class="evidence-explanation">This reference supports the use of alcohol septal ablation as a proven therapy for hypertrophic cardiomyopathy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/10980888" target="_blank">PMID:10980888</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Following balloon inflation and intracoronary myocardial contrast echocardiography, ethyl alcohol is injected through the catheter lumen to cause proximal interventricular septum infarction and relief of outflow tract obstruction."</div>
                
                
                <div class="evidence-explanation">This reference supports the description of alcohol septal ablation as a minimally invasive procedure to reduce obstruction by injecting alcohol.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Implantable Cardioverter Defibrillator (ICD)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000004" target="_blank">
                            MAXO:0000004
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Prevents sudden cardiac death in high-risk patients</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26002383" target="_blank">PMID:26002383</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Nevertheless, several observational clinical studies have shown that the ICD reliably terminates life-threatening ventricular tachyarrhythmias in HCM, and is largely responsible for reducing HCM mortality to 0.5% per year, by preventing SD and changing the natural course of the disease."</div>
                
                
                <div class="evidence-explanation">This excerpt supports the statement by showing that ICDs prevent sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36396186" target="_blank">PMID:36396186</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Implantable cardioverter-defibrillators are the mainstay of therapy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy (HCM)."</div>
                
                
                <div class="evidence-explanation">This excerpt also supports the statement by confirming that ICDs are a primary treatment used to prevent sudden cardiac death in high-risk HCM patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22687587" target="_blank">PMID:22687587</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Risk of sudden death correlates with maximum left ventricular (LV) wall thickness. Massive LV thickening of 30 mm or more is an indication for primary prevention of sudden death with an implanted defibrillator."</div>
                
                
                <div class="evidence-explanation">This excerpt provides specific criteria for using ICDs as a preventative measure in patients with significant hypertrophic cardiomyopathy, further supporting the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">üåç</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">None Applicable</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23692943" target="_blank">PMID:23692943</a>
                    </span>
                    
                    <span class="evidence-support support-WRONG_STATEMENT">WRONG_STATEMENT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hypertrophic cardiomyopathy is a complex cardiovascular disorder particularly sensitive to environmental changes and physiologic stress. Warm weather and strenuous activity can be a dangerous combination for people that have hypertrophic cardiomyopathy. Often sudden cardiac death is the first..."</div>
                
                
                <div class="evidence-explanation">The statement that hypertrophic cardiomyopathy is not influenced by environmental factors is incorrect. Environmental factors and physiological stress are significant factors in the management and severity of hypertrophic cardiomyopathy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Troponin
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: During myocardial stress or damage</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24011925" target="_blank">PMID:24011925</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The results demonstrated that hs-cTnT was elevated in a significant number of our HCM patients; therefore, hs-cTnT can be introduced as a valuable marker of myocardial injury in HCM patients."</div>
                
                
                <div class="evidence-explanation">This study observes and confirms that hypertrophic cardiomyopathy (HCM) patients often have elevated levels of high-sensitivity cardiac troponin T (hs-cTnT), indicating its utility as a marker of myocardial injury.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15631686" target="_blank">PMID:15631686</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"More than 200 mutations in the cardiac sarcomeric proteins, including myosin heavy and light chains, actin, troponin, tropomyosin, myosin-binding protein-C, and titin/connectin, have been found to cause various types of cardiomyopathy in human since 1990..."</div>
                
                
                <div class="evidence-explanation">This study indicates that mutations in cardiac sarcomeric proteins, including troponin subunits, are linked to various types of cardiomyopathy, including hypertrophic cardiomyopathy, leading to myocardial damage where elevated troponin can be expected.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Hypertrophic Cardiomyopathy
synonyms:
- HCM
category: Complex
parents:
- Cardiovascular Disease
- Genetic Disorder
has_subtypes:
- name: Obstructive HCM
  description: The thickened heart muscle obstructs blood flow out of the left ventricle.
  evidence:
  - reference: PMID:38368032
    supports: PARTIAL
    snippet: Obstruction to left ventricular outflow occurs in approximately 60% of
      patients.
    explanation: The provided literature states that obstruction occurs in approximately
      60% of HCM patients, indicating that not all HCM cases are obstructive. Thus,
      the statement that the thickened heart muscle obstructs blood flow out of the
      left ventricle can be recognized as a subtype known as obstructive HCM but does
      not apply to all HCM patients.
  - reference: PMID:35555885
    supports: PARTIAL
    snippet: Left ventricular (LV) wall thickening, or LV hypertrophy (LVH), is common
      and occurs in diverse conditions including hypertrophic cardiomyopathy (HCM)...
    explanation: The literature indicates that LV hypertrophy (LVH) occurs in HCM
      alongside various conditions. However, it characterizes different forms, not
      solely obstructive HCM, thereby acknowledging the partial correctness of the
      subtype Obstructive HCM but not exclusively.
  - reference: PMID:20560010
    supports: SUPPORT
    snippet: Left ventricular outflow tract obstruction (LVOTO) is one of the defining
      features of hypertrophic cardiomyopathy (HCM)...
    explanation: This specific literature confirms that left ventricular outflow tract
      obstruction (LVOTO) is a defining feature of HCM, thereby supporting the statement
      regarding the thickened heart muscle obstructing blood flow out of the left
      ventricle.
- name: Non-Obstructive HCM
  description: The heart muscle is thickened, but blood flow is not significantly
    obstructed.
  evidence:
  - reference: PMID:34126727
    supports: SUPPORT
    snippet: Patients with non-obstructive HCM... According to the characteristics
      of cardiac morphology and function shown by echocardiography, the patients were
      divided into common type, dilated type, restricted type and reduced ejection
      fraction type.
    explanation: The reference describes non-obstructive hypertrophic cardiomyopathy
      (HCM) as a subtype of HCM characterized by different clinical subtypes based
      on cardiac morphology and function, supporting the statement that non-obstructive
      HCM involves thickened heart muscle without significant obstruction of blood
      flow.
  - reference: PMID:35555885
    supports: SUPPORT
    snippet: Left ventricular (LV) wall thickening, or LV hypertrophy (LVH), is common
      and occurs in diverse conditions including hypertrophic cardiomyopathy (HCM)...Although
      various diseases share LV wall thickening as a common feature, the histologic
      changes that underscore each disease are distinct.
    explanation: This reference supports the statement by acknowledging that hypertrophic
      cardiomyopathy can include conditions with thickened heart muscle where the
      histological features differ, indicating diverse subtypes including non-obstructive
      forms.
prevalence:
- population: General Population
  percentage: 0.2
  evidence:
  - reference: PMID:25814232
    supports: PARTIAL
    snippet: For the past 20 years, most data have supported the occurrence of HCM
      at about 1 in 500.
    explanation: 1 in 500 translates to 0.2%, which supports the statement. However,
      the statement could be conflicting with the suggestion that HCM might be more
      common than previously estimated.
  - reference: PMID:34969871
    supports: PARTIAL
    snippet: Between 2010 and 2018, prevalence increased for ARVC by 180% and HCM
      by 9%.
    explanation: While the statement of HCM prevalence being 0.2% is approximately
      correct, recognition of HCM prevalence seems to have increased, indicating it
      could be more common now.
  - reference: PMID:33623987
    supports: PARTIAL
    snippet: Currently, available estimates of prevalence and incidence of CMPs are
      based on clinical data, collected with a wide variability in population-source,
      and before the genetic testing evolved as a standard diagnostic tool.
    explanation: Prevalence estimates for HCM might vary based on the population and
      advances in diagnostic tools, suggesting that 0.2% could be an estimate but
      with existing variability.
progression:
- phase: Onset
  evidence:
  - reference: PMID:25897040
    supports: SUPPORT
    snippet: Myocardial fibrosis in HCM is a progressive phenomenon. Non-apical phenotype
      and a higher LGE extent at CMR-1 are both associated with greater LGE progression.
    explanation: The literature supports that hypertrophic cardiomyopathy (HCM) can
      progress over time, which implies progression from an initial onset phase.
  - reference: PMID:22158452
    supports: SUPPORT
    snippet: Progressive heart failure associated with left ventricular remodeling
      and systo-diastolic dysfunction is one of the most severe complications of hypertrophic
      cardiomyopathy (HCM).
    explanation: The progression of hypertrophic cardiomyopathy (HCM) through various
      stages, including an onset phase, is indicated by the reference to progressive
      heart failure.
  - reference: PMID:29111210
    supports: SUPPORT
    snippet: Hypertrophic cardiomyopathy (HC) has been characterized as a generally
      progressive genetic heart disease...
    explanation: The statement that HC is generally progressive suggests that there
      is an initial onset phase followed by further disease progression.
- age_range: Adolescence-Adulthood
  evidence:
  - reference: PMID:29622585
    supports: SUPPORT
    snippet: In the subset of patients with serial imaging, statistically significant
      increases in LGE, LV mass, and left atrial size were detected over 2.5 years,
      indicating disease progression over time.
    explanation: This study shows significant disease progression, including increases
      in late gadolinium enhancement (LGE), left ventricular (LV) mass, and left atrial
      size, indicating that hypertrophic cardiomyopathy progresses over time from
      adolescence into adulthood.
  - reference: PMID:29710196
    supports: SUPPORT
    snippet: Pediatric-onset HCM is rare and associated with adverse outcomes driven
      mainly by arrhythmic events. Risk extends well beyond adolescence, which calls
      for unchanged clinical surveillance into adulthood.
    explanation: This study highlights that pediatric-onset HCM progresses into adulthood
      and is associated with adverse outcomes, supporting continuous clinical surveillance.
pathophysiology:
- name: Sarcomere Protein Mutations
  description: Genetic mutations affecting the proteins of the cardiac sarcomere lead
    to abnormal thickening of the heart muscle. The central biophysical abnormality
    is sarcomere hypercontractility with increased myosin duty ratio and power, resulting
    in impaired relaxation and elevated energetic cost of contraction.
  cell_types:
  - preferred_term: Cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  locations:
  - preferred_term: left ventricle
    term:
      id: UBERON:0002084
      label: heart left ventricle
  - preferred_term: interventricular septum
    term:
      id: UBERON:0002094
      label: interventricular septum
  cellular_components:
  - preferred_term: sarcomere
    term:
      id: GO:0030017
      label: sarcomere
  - preferred_term: thick filament
    term:
      id: GO:0005863
      label: myosin filament
  - preferred_term: thin filament
    term:
      id: GO:0005865
      label: striated muscle thin filament
  biological_processes:
  - preferred_term: muscle contraction
    term:
      id: GO:0006936
      label: muscle contraction
  - preferred_term: regulation of heart contraction
    term:
      id: GO:0008016
      label: regulation of heart contraction
  - preferred_term: ATP hydrolysis activity
    term:
      id: GO:0016887
      label: ATP hydrolysis activity
  evidence:
  - reference: PMID:16416046
    supports: SUPPORT
    snippet: Hypertrophic Cardiomyopathy (HCM) is a relatively common primary cardiac
      disorder defined as the presence of a hypertrophied left ventricle... to date,
      270 independent mutations in nine sarcomeric protein genes have been linked
      to Familial Hypertrophic Cardiomyopathy (FHC)...
    explanation: The reference discusses how mutations in sarcomeric protein genes
      are linked to hypertrophic cardiomyopathy, which leads to heart muscle thickening.
  - reference: PMID:36797478
    supports: SUPPORT
    snippet: The most common form of genetic heart disease is hypertrophic cardiomyopathy
      (HCM), which is caused by variants in cardiac sarcomeric genes and leads to
      abnormal heart muscle thickening.
    explanation: This reference directly states that HCM is caused by variants in
      sarcomeric genes resulting in heart muscle thickening.
  - reference: PMID:28645928
    supports: SUPPORT
    snippet: For example, increased myosin heavy chain (MHC) binding and ATP utilization
      lead to the hypercontractile sarcomere in HCM...
    explanation: This reference explains how specific mutations in sarcomeric proteins
      lead to hypercontractility, a feature of muscle thickening in HCM.
  - reference: PMID:37060436
    supports: SUPPORT
    snippet: Recent advances in our mechanistic understanding of sarcomere pathophysiology
      include high-resolution molecular models of sarcomere components and the identification
      of the myosin super-relaxed state.
    explanation: This reference details how understanding sarcomere function and its
      pathophysiology relates to mutations leading to cardiomyopathy, thereby supporting
      the statement about genetic mutations affecting sarcomere proteins.
- name: Myocyte Disarray
  description: Disorganization of heart muscle cells contributes to the stiffness
    and dysfunction of the myocardium. Loss of physiological fiber alignment and
    orientation creates structural abnormalities that impair contractile efficiency
    and promote arrhythmogenic substrate.
  cell_types:
  - preferred_term: Cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  locations:
  - preferred_term: ventricular myocardium
    term:
      id: UBERON:0002084
      label: heart left ventricle
  evidence:
  - reference: PMID:33447843
    supports: SUPPORT
    snippet: Myocardial disarray is defined as disorganized cardiomyocyte spatial
      distribution, with loss of physiological fibre alignment and orientation.
    explanation: The paper discusses how myocardial disarray is a typical feature
      of hypertrophic cardiomyopathy (HCM), implying its role in myocardial dysfunction.
  - reference: PMID:7665141
    supports: SUPPORT
    snippet: Genes on five loci on separate chromosomes are responsible for a familial
      disease in which all or part of the ventricular muscle undergoes thickening
      with a histological picture of irregular hypertrophy and disorganized arrangement
      of myocytes (disarray).
    explanation: This indicates that myocyte disarray is a feature of the disease,
      contributing to the thickening and impaired function of the myocardium.
  - reference: PMID:11040002
    supports: SUPPORT
    snippet: Within an individual heart the magnitude of hypertrophy correlated with
      the severity of fibrosis (p = 0.006) and disarray (p = 0.0002).
    explanation: The correlation between hypertrophy, fibrosis, and disarray supports
      the statement that myocyte disarray contributes to myocardial dysfunction.
- name: Myocardial Fibrosis
  description: Increased collagen deposition by interstitial cells contributes to
    myocardial stiffness. Activation of TGF-beta and MAPK signaling pathways promotes
    extracellular matrix remodeling and fibrosis, which is a progressive phenomenon
    associated with greater disease severity.
  cell_types:
  - preferred_term: Interstitial Cells
    term:
      id: CL:4030031
      label: interstitial cell
  - preferred_term: cardiac fibroblast
    term:
      id: CL:0002548
      label: fibroblast of cardiac tissue
  locations:
  - preferred_term: myocardial interstitium
    term:
      id: UBERON:0002084
      label: heart left ventricle
  biological_processes:
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
  - preferred_term: response to TGF-beta
    term:
      id: GO:0071559
      label: response to transforming growth factor beta
  cellular_components:
  - preferred_term: extracellular matrix
    term:
      id: GO:0031012
      label: extracellular matrix
  evidence:
  - reference: PMID:1414892
    supports: SUPPORT
    snippet: It appears that increased collagen production is mainly responsible for
      the functional consequences of structural remodelling
    explanation: The increased collagen production discussed here is consistent with
      the contribution of interstitial cells to myocardial stiffness.
  - reference: PMID:25573453
    supports: SUPPORT
    snippet: Tissue from cats with pre-clinical HCM also had a higher number of neutrophils
      and a greater collagen content than the myocardium of normal cats.
    explanation: This study shows increased collagen deposition, contributing to myocardial
      stiffness, aligning with the statement.
  - reference: PMID:29522370
    supports: SUPPORT
    snippet: We conclude that myocardial macrophages play an important role in the
      time-dependent increases in SPARC that enhance postsynthetic collagen processing,
      insoluble collagen content, and myocardial stiffness and contribute to the development
      of fibrosis.
    explanation: The role of interstitial cells like macrophages in increasing collagen
      content supports the statement.
  - reference: PMID:12510171
    supports: SUPPORT
    snippet: The myocardial collagen matrix consists of a network of fibrillar collagen
      which is intimately connected to the myocyte.
    explanation: The mention of the collagen matrix supports the idea of increased
      collagen deposition by interstitial cells contributing to myocardial stiffness.
- name: Altered Calcium Handling
  description: Increased myofilament calcium sensitivity and impaired diastolic calcium
    removal lead to diastolic dysfunction and promote pro-hypertrophic signaling.
    Altered calcium homeostasis contributes to both contractile abnormalities and
    arrhythmogenic substrate.
  cell_types:
  - preferred_term: Cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: calcium ion transport
    term:
      id: GO:0006816
      label: calcium ion transport
  - preferred_term: regulation of cardiac muscle contraction
    term:
      id: GO:0055117
      label: regulation of cardiac muscle contraction
  cellular_components:
  - preferred_term: sarcoplasmic reticulum
    term:
      id: GO:0016529
      label: sarcoplasmic reticulum
  locations:
  - preferred_term: left ventricle
    term:
      id: UBERON:0002084
      label: heart left ventricle
  notes: Calcium dysregulation is a downstream consequence of sarcomere mutations
    that impairs relaxation and triggers hypertrophic remodeling
- name: Mitochondrial Dysfunction
  description: Elevated energetic cost of sarcomere hypercontractility leads to mitochondrial
    stress and downregulation of energy metabolism pathways. Impaired ATP production
    contributes to contractile dysfunction and cellular remodeling.
  cell_types:
  - preferred_term: Cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: ATP metabolic process
    term:
      id: GO:0046034
      label: ATP metabolic process
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
  cellular_components:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  locations:
  - preferred_term: myocardium
    term:
      id: UBERON:0002084
      label: heart left ventricle
  notes: Energy metabolism dysfunction is a consistent finding across HCM genotypes
    in tissue omics studies
- name: Left Ventricular Outflow Tract Obstruction
  description: Asymmetric septal hypertrophy combined with systolic anterior motion
    of the mitral valve creates dynamic obstruction to blood flow. Venturi forces
    draw the mitral valve toward the septum, elevating wall stress and contributing
    to ischemia and further hypertrophic remodeling.
  cell_types:
  - preferred_term: Cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  locations:
  - preferred_term: interventricular septum
    term:
      id: UBERON:0002094
      label: interventricular septum
  - preferred_term: mitral valve
    term:
      id: UBERON:0002135
      label: mitral valve
  - preferred_term: left ventricular outflow tract
    term:
      id: UBERON:0016480
      label: cardiac outflow tract
  notes: Occurs in approximately 60% of HCM patients and is a defining feature of
    obstructive HCM
phenotypes:
- category: Cardiovascular
  name: Chest Pain
  frequency: FREQUENT
  evidence:
  - reference: PMID:34533409
    supports: SUPPORT
    snippet: Hypertrophic cardiomyopathy (HCM) is a complex disease characterized
      by thickening of the cardiac muscle. Common symptoms include chest pain, shortness
      of breath, palpitations, fatigue and syncope (fainting), which are often confused
      for other conditions.
    explanation: This literature supports the statement as it lists chest pain as
      a common symptom of Hypertrophic Cardiomyopathy.
  phenotype_term:
    preferred_term: Chest pain
    term:
      id: HP:0100749
      label: Chest pain
- category: Cardiovascular
  name: Dyspnea
  frequency: FREQUENT
  evidence:
  - reference: PMID:29655822
    supports: SUPPORT
    snippet: Heart failure (HF), characterized by excessive exertional dyspnea, is
      a common complication within the broad clinical spectrum of hypertrophic cardiomyopathy
      (HCM).
    explanation: The literature provided mentions that exertional dyspnea is common
      in patients with hypertrophic cardiomyopathy, supporting the statement that
      dyspnea is a common phenotype of HCM.
  phenotype_term:
    preferred_term: Dyspnea
    term:
      id: HP:0002094
      label: Dyspnea
- category: Cardiovascular
  name: Syncope
  frequency: OCCASIONAL
  notes: Often triggered by exertion
  evidence:
  - reference: PMID:29150126
    supports: SUPPORT
    snippet: Clinical manifestations of Hypertrophic Cardiomyopathy include shortness
      of breath, chest pain, palpitations and syncope, which are related to the onset
      of diastolic dysfunction, left ventricular outflow tract obstruction, ischemia,
      atrial fibrillation and abnormal vascular responses.
    explanation: The excerpt directly states that syncope is a clinical manifestation
      of hypertrophic cardiomyopathy.
  - reference: PMID:36442670
    supports: SUPPORT
    snippet: &#39;Syncope in hypertrophic cardiomyopathy: Explaining the unexplained.&#39;
    explanation: Syncope is highlighted as a phenomenon occurring in individuals with
      hypertrophic cardiomyopathy.
  - reference: PMID:29761339
    supports: SUPPORT
    snippet: Syncope and presyncope-in addition to extremely variable cardiac symptoms
      (dyspnea and angina)-are common.
    explanation: The text explicitly mentions syncope as a common symptom in hypertrophic
      cardiomyopathy patients.
  phenotype_term:
    preferred_term: Syncope
    term:
      id: HP:0001279
      label: Syncope
- category: Cardiovascular
  name: Arrhythmias
  frequency: FREQUENT
  evidence:
  - reference: PMID:34969871
    supports: SUPPORT
    snippet: Study aims were to estimate the population-diagnosed prevalence of cardiomyopathies
      and describe the temporal relationship between a diagnosis of cardiomyopathy
      with HF and arrhythmia... Between 2010 and 2018, prevalence increased for ARVC
      by 180% and HCM by 9%.
    explanation: The study indicates a relationship between hypertrophic cardiomyopathy
      (HCM) and arrhythmias, supporting the statement that arrhythmias are a common
      cardiovascular phenotype of HCM.
  - reference: PMID:7201843
    supports: SUPPORT
    snippet: The patients with hypertrophic cardiomyopathy showed a significant increase
      in supraventricular extrasystoles/24 hours, supraventricular arrhythmias, high
      grade ventricular arrhythmia, and the number of patients with more than 10 ventricular
      extrasystoles every 24 hours when compared with the other groups.
    explanation: This study directly assesses the prevalence and types of arrhythmias
      in patients with hypertrophic cardiomyopathy, confirming that arrhythmias are
      a common phenotype.
  - reference: PMID:3158692
    supports: SUPPORT
    snippet: Frequent ventricular premature complexes, complex ventricular ectopic
      activity and asymptomatic ventricular tachycardia are common to both hypertrophic
      and dilated cardiomyopathy; in both conditions, sudden death is a common occurrence.
    explanation: This reference mentions common arrhythmic events in hypertrophic
      cardiomyopathy, supporting the idea that arrhythmias are a common cardiovascular
      phenotype in HCM.
  phenotype_term:
    preferred_term: Arrhythmias
    term:
      id: HP:0011675
      label: Arrhythmia
- category: Cardiovascular
  frequency: FREQUENT
  name: Arrhythmias
  notes: Abnormal heart rhythms are common. Can include atrial fibrillation and ventricular
    arrhythmias.
  sequelae:
  - target: Palpitations
  - target: Sudden Cardiac Death
  evidence:
  - reference: PMID:23124402
    supports: SUPPORT
    snippet: Hypertrophic cardiomyopathy is the most common genetic cardiovascular
      disorder and the leading cause of sudden cardiac death in the young. This article
      reviews the ventricular arrhythmias associated with hypertrophic cardiomyopathy.
    explanation: The reference confirms that hypertrophic cardiomyopathy is associated
      with ventricular arrhythmias and is a leading cause of sudden cardiac death.
  - reference: PMID:28602671
    supports: SUPPORT
    snippet: Patients with HCM are predisposed to developing atrial fibrillation (AF)
      due primarily to advanced diastolic dysfunction and left atrial (LA) dilatation
      and remodelling.
    explanation: The reference confirms that atrial fibrillation is common in patients
      with hypertrophic cardiomyopathy.
  - reference: PMID:29203161
    supports: SUPPORT
    snippet: Cardiac arrhythmias refer to any abnormality or disturbance in the normal
      activation sequence of the myocardium and may be indicative of structural heart
      disease and the cause of significant cardiovascular complications and sudden
      cardiac death.
    explanation: The reference discusses the role of arrhythmias in structural heart
      disease, including hypertrophic cardiomyopathy, and their association with significant
      cardiovascular complications and sudden cardiac death.
  - reference: PMID:11174912
    supports: SUPPORT
    snippet: Ventricular arrhythmias in the athlete generally occur in the setting
      of structural heart disease that is genetically determined (hypertrophic cardiomyopathy,
      arrhythmogenic right ventricular dysplasia, anomalous coronary arteries) or
      acquired (coronary artery disease, myocarditis, idiopathic dilated cardiomyopathies).
    explanation: The reference confirms that ventricular arrhythmias are common in
      hypertrophic cardiomyopathy, particularly in athletes.
  phenotype_term:
    preferred_term: Arrhythmias
    term:
      id: HP:0011675
      label: Arrhythmia
- category: Cardiovascular
  frequency: OCCASIONAL
  name: Mitral Valve Regurgitation
  notes: Thickened heart muscle can affect mitral valve function, causing leakage.
  evidence:
  - reference: PMID:21909825
    supports: SUPPORT
    snippet: Elongation and pathological thickening of the mitral valve (MV) is commonly
      seen in hypertrophic cardiomyopathy (HCM)... failure of either to optimally
      adapt in this setting can result in mitral regurgitation.
    explanation: The reference discusses the common occurrence of mitral valve elongation
      and thickening in HCM, which can lead to mitral regurgitation.
  - reference: PMID:35644869
    supports: SUPPORT
    snippet: &#39;RESULTS: Significant (more than mild) MR was a significant univariate
      predictor of all the three LA strain values&#39;
    explanation: This study shows that mitral regurgitation (MR) is a significant
      factor in patients with hypertrophic cardiomyopathy (HCM), supporting the statement
      that thickened heart muscle can affect mitral valve function, causing leakage.
  - reference: PMID:37563454
    supports: SUPPORT
    snippet: However, the interplay between these conditions is increasingly being
      recognized and they frequently coexist, as in the paradigmatic examples of dilated
      cardiomyopathy and hypertrophic cardiomyopathy, which are often complicated
      by the occurrence of mitral regurgitation.
    explanation: The reference indicates that hypertrophic cardiomyopathy is often
      complicated by mitral regurgitation, supporting the statement.
  - reference: PMID:37574021
    supports: SUPPORT
    snippet: OHCM patients with MAC had a worse prognosis and more recurrent mitral
      valve regurgitation than those without MAC after septal myectomy.
    explanation: This study indicates that mitral valve regurgitation is a complication
      in hypertrophic obstructive cardiomyopathy (OHCM), supporting the statement.
- category: Systemic
  frequency: OCCASIONAL
  name: Fatigue
  notes: Due to reduced cardiac output and efficiency.
  evidence:
  - reference: PMID:34533409
    supports: SUPPORT
    snippet: Common symptoms include chest pain, shortness of breath, palpitations,
      fatigue and syncope (fainting)...
    explanation: The reference mentions fatigue as a common symptom of hypertrophic
      cardiomyopathy, supporting the statement that fatigue occurs occasionally in
      this condition.
  - reference: PMID:37715354
    supports: SUPPORT
    snippet: A 59-year-old man was referred for SSM as dyspnoea and low threshold
      muscle fatigue associated to severe left ventricular outflow obstruction...
    explanation: The reference describes a patient with hypertrophic obstructive cardiomyopathy
      experiencing muscle fatigue, aligning with the statement that fatigue is occasionally
      observed due to reduced cardiac output and efficiency.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Cardiovascular
  name: Palpitations
  frequency: FREQUENT
  notes: Often associated with atrial fibrillation and ventricular arrhythmias
  phenotype_term:
    preferred_term: Palpitations
    term:
      id: HP:0001962
      label: Palpitations
- category: Cardiovascular
  name: Sudden Cardiac Death
  frequency: OCCASIONAL
  notes: Highest risk in young patients and those with sarcomere-positive disease.
    Leading cause of sudden death in young athletes.
  phenotype_term:
    preferred_term: Sudden Cardiac Death
    term:
      id: HP:0001645
      label: Sudden cardiac death
- category: Cardiovascular
  name: Left Ventricular Hypertrophy
  frequency: OBLIGATE
  notes: Defining feature of HCM; often asymmetric with septal predominance
  phenotype_term:
    preferred_term: Left ventricular hypertrophy
    term:
      id: HP:0001712
      label: Left ventricular hypertrophy
- category: Cardiovascular
  name: Atrial Fibrillation
  frequency: FREQUENT
  notes: Due to advanced diastolic dysfunction and left atrial dilatation and remodeling.
    Genotype-positive status associated with higher lifetime hazard.
  phenotype_term:
    preferred_term: Atrial fibrillation
    term:
      id: HP:0005110
      label: Atrial fibrillation
biochemical:
- name: Troponin
  presence: Elevated
  context: During myocardial stress or damage
  evidence:
  - reference: PMID:24011925
    supports: SUPPORT
    snippet: The results demonstrated that hs-cTnT was elevated in a significant number
      of our HCM patients; therefore, hs-cTnT can be introduced as a valuable marker
      of myocardial injury in HCM patients.
    explanation: This study observes and confirms that hypertrophic cardiomyopathy
      (HCM) patients often have elevated levels of high-sensitivity cardiac troponin
      T (hs-cTnT), indicating its utility as a marker of myocardial injury.
  - reference: PMID:15631686
    supports: SUPPORT
    snippet: More than 200 mutations in the cardiac sarcomeric proteins, including
      myosin heavy and light chains, actin, troponin, tropomyosin, myosin-binding
      protein-C, and titin/connectin, have been found to cause various types of cardiomyopathy
      in human since 1990...
    explanation: This study indicates that mutations in cardiac sarcomeric proteins,
      including troponin subunits, are linked to various types of cardiomyopathy,
      including hypertrophic cardiomyopathy, leading to myocardial damage where elevated
      troponin can be expected.
diagnosis:
- name: Echocardiogram
  notes: Shows left ventricular hypertrophy and outflow obstruction if present
  evidence:
  - reference: PMID:22948303
    supports: SUPPORT
    snippet: The evaluation of hypertrophic cardiomyopathy incorporates methods based
      on the ultrasound image, which, along with MRI, allow recognizing ventricular
      obstruction generating mechanisms, thus facilitating the diagnosis and management
      of obstructive and latent obstructive forms.
    explanation: The text indicates that echocardiographic imaging is crucial for
      identifying left ventricular obstruction in hypertrophic cardiomyopathy, supporting
      the statement about echocardiogram diagnosis.
  - reference: PMID:37160197
    supports: SUPPORT
    snippet: This document provides an additional practical framework for optimal
      image and measurement acquisition and guidance on how to tailor the echocardiography
      examination for individuals with HCM.
    explanation: This supports that echocardiogram (which includes ultrasound) is
      a fundamental diagnostic tool for hypertrophic cardiomyopathy.
  - reference: PMID:133253
    supports: SUPPORT
    snippet: Asymmetric septal hypertrophy was demonstrated in both obstructive and
      nonobstructive HCM. In all cases of HCM studied, the thickness of the interventricular
      septum was 1.4 cm or more (1.4-3.7 cm) ... A systolic anterior movement of the
      mitral valve (SAM) was observed in obstructive cases only and characterized
      by a large backward component in late systole and an extreme approximation to
      the interventricular septum at its peak.
    explanation: The echocardiographic study clearly demonstrates its effectiveness
      in diagnosing features of HCM including left ventricular hypertrophy and outflow
      obstruction.
- name: Electrocardiogram
  notes: May show signs of left ventricular hypertrophy or arrhythmias
  evidence:
  - reference: PMID:32639329
    supports: PARTIAL
    snippet: In our study, only a few ECG voltage criteria used for the detection
      of LVH in clinical practice showed an acceptable performance in the HCM population.
    explanation: While ECG can show signs of left ventricular hypertrophy, its overall
      diagnostic accuracy in hypertrophic cardiomyopathy (HCM) populations is limited.
  - reference: PMID:37579849
    supports: PARTIAL
    snippet: Although the 12‚Äëlead electrocardiogram (ECG) is abnormal in most patients
      with hypertrophic cardiomyopathy (HCM), some present normal ECG.
    explanation: The ECG can be useful for diagnosing HCM, but a normal ECG does not
      rule out the condition.
  - reference: PMID:23704850
    supports: SUPPORT
    snippet: Electrocardiogram typically shows repolarization changes and giant (&gt;10
      mm), inverted T waves in the anterolateral leads.
    explanation: Specific ECG patterns can be indicative of certain variants of HCM.
  - reference: PMID:30739754
    supports: PARTIAL
    snippet: The minimum check-up must include an electrocardiogram and a transthoracic
      echocardiography, which will most of the time be completed by magnetic resonance
      imaging.
    explanation: While ECG is part of the diagnostic process, it alone may not be
      sufficient for a conclusive diagnosis.
  - reference: PMID:25060129
    supports: SUPPORT
    snippet: Attention is drawn to the finding that in many differing etiologies of
      left ventricular hypertrophy ST-T-wave changes commonly referred to as &#39;strain&#39;-pattern
      are a harbinger of an increased risk of malignant cardiac arrhythmias and sudden
      death.
    explanation: ECG changes such as ST-T wave abnormalities are relevant for diagnosing
      LVH in the context of HCM.
genetic:
- name: MYH7
  association: Pathogenic Variants
  evidence:
  - reference: PMID:38423942
    supports: SUPPORT
    snippet: &#39;Hypertrophic cardiomyopathy: New pathogenic variant in MYH7.&#39;
    explanation: The title of the referenced article explicitly indicates the association
      of a pathogenic variant in MYH7 with hypertrophic cardiomyopathy.
  - reference: PMID:23905887
    supports: SUPPORT
    snippet: Genetic mutations can be identified in approximately 60% of patients;
      these are commonest in genes that encode proteins of the cardiac sarcomere.
    explanation: While the specific mutations in MYH7 are not detailed in this snippet,
      the article supports the general assertion that genetic mutations, particularly
      in sarcomeric genes like MYH7, are common in hypertrophic cardiomyopathy.
  - reference: PMID:31735781
    supports: SUPPORT
    snippet: By NGS, we determined that these subjects with HCM symptoms carried a
      missense heterozygous genetic mutation c.2632C&gt;A (p.V878L) in the myosin heavy
      chain 7 (MYH7) gene with an autosomal dominant pattern of inheritance.
    explanation: The article details a specific pathogenic variant (p.V878L) in the
      MYH7 gene associated with hypertrophic cardiomyopathy.
  - reference: PMID:36797478
    supports: SUPPORT
    snippet: The dominant-negative c.1208G&gt;A (p.R403Q) pathogenic variant (PV) in
      beta-myosin (MYH7) is a common and well-studied PV that leads to increased cardiac
      contractility and HCM onset.
    explanation: The article identifies the commonly studied pathogenic variant (p.R403Q)
      in MYH7 which leads to hypertrophic cardiomyopathy.
  - reference: PMID:30681346
    supports: SUPPORT
    snippet: Of 33 HCM genes, only 8 (24%) were categorized as definitive (MYBPC3,
      MYH7, TNNT2, TNNI3, TPM1, ACTC1, MYL2, and MYL3).
    explanation: The article categorizes MYH7 as one of the &#39;definitive&#39; genes associated
      with hypertrophic cardiomyopathy.
  - reference: PMID:37565978
    supports: SUPPORT
    snippet: MYH7 variants cause hypertrophic cardiomyopathy (HCM), noncompaction
      cardiomyopathy (NCCM), and dilated cardiomyopathy (DCM).
    explanation: The article explicitly states that MYH7 variants cause hypertrophic
      cardiomyopathy, reinforcing the genetic association.
- name: MYBPC3
  association: Pathogenic Variants
  evidence:
  - reference: PMID:34180388
    supports: SUPPORT
    snippet: The proband carries a novel heterozygous nonsense variant of MYBPC3:c.2731G
      &gt; T (p.E911X) ... suggesting the functional damages to the protein of MYBPC3.
    explanation: The study identifies a novel pathogenic variant in MYBPC3 associated
      with hypertrophic cardiomyopathy.
  - reference: PMID:24240729
    supports: SUPPORT
    snippet: The second wave started in 1995 by the discovery that mutations in the
      gene encoding cMyBP-C cause hypertrophic cardiomyopathy (HCM).
    explanation: This review discusses that mutations in MYBPC3 (which encodes cMyBP-C)
      cause HCM.
  - reference: PMID:37409452
    supports: SUPPORT
    snippet: The 2 sarcomere genes most commonly associated with hypertrophic cardiomyopathy
      (HCM), MYBPC3 (myosin-binding protein C3)...
    explanation: Study identifies MYBPC3 as a common gene associated with hypertrophic
      cardiomyopathy.
  - reference: PMID:35544052
    supports: SUPPORT
    snippet: Pathogenic variants associated with inherited cardiomyopathy ... MYBPC3
      ... were classified ...
    explanation: This study includes MYBPC3 as one of the genes with pathogenic variants
      associated with inherited cardiomyopathy.
- name: TNNT2
  association: Pathogenic Variants
  notes: Can present with relatively modest LVH but disproportionate arrhythmic risk
  evidence:
  - reference: PMID:33588347
    supports: SUPPORT
    snippet: Variants were identified and annotated using in silico tools, and further
      classified as pathogenic or benign according to the American College of Medical
      Genetics and Genomics guidelines. Variants with functional effects were identified...and
      TNNT2...
    explanation: The study identifies pathogenic variants in TNNT2 among patients
      with hypertrophic cardiomyopathy, supporting the genetic association.
  - reference: PMID:7665141
    supports: SUPPORT
    snippet: Genes on five loci on separate chromosomes are responsible for a familial
      disease in which all or part of the ventricular muscle undergoes thickening
      with a histological picture of irregular hypertrophy and disorganized arrangement
      of myocytes (disarray). The three genes identified so far encode for beta heavy
      chain myosin (chromosome 14), troponin T (chromosome 1) and alpha tropomyosin
      (chromosome 15).
    explanation: The study reveals that the troponin T gene (TNNT2) is one of the
      implicated genes in hypertrophic cardiomyopathy.
- name: ALPK3
  association: Pathogenic Variants
  notes: Emerging gene; biallelic variants linked to pediatric-onset cardiomyopathy,
    heterozygous variants show variable adult-onset HCM. Involved in sarcomere and
    nuclear signaling.
- name: FHOD3
  association: Pathogenic Variants
  notes: Emerging gene; formin homology domain protein regulating actin cytoskeleton.
    Variants perturb myofibrillogenesis and cytoskeletal integrity, contributing
    to sarcomere remodeling.
- name: TRIM63
  association: Pathogenic Variants
  notes: Emerging gene; muscle-specific RING-finger protein (MuRF1) involved in proteostasis.
    Loss- or gain-of-function variants may alter sarcomeric protein turnover. Homozygous
    cases reported with severe remodeling.
- name: SVIL
  association: Pathogenic Variants
  notes: Emerging gene; supervillin is a cytoskeletal-membrane linker. Rare variants
    recently reported in HCM cohorts, hypothesized to affect sarcomere-cytoskeleton
    coupling. Associated with apical/septal phenotypes in some populations.
environmental:
- name: None Applicable
  evidence:
  - reference: PMID:23692943
    supports: WRONG_STATEMENT
    snippet: Hypertrophic cardiomyopathy is a complex cardiovascular disorder particularly
      sensitive to environmental changes and physiologic stress. Warm weather and
      strenuous activity can be a dangerous combination for people that have hypertrophic
      cardiomyopathy. Often sudden cardiac death is the first symptom of the disorder.
    explanation: The statement that hypertrophic cardiomyopathy is not influenced
      by environmental factors is incorrect. Environmental factors and physiological
      stress are significant factors in the management and severity of hypertrophic
      cardiomyopathy.
treatments:
- name: Beta Blockers
  description: Used to reduce heart rate and improve symptoms
  evidence:
  - reference: PMID:35450574
    supports: SUPPORT
    snippet: Beta-Blockers and Exercise Hemodynamics in Hypertrophic Cardiomyopathy.
    explanation: This reference discusses the use of beta-blockers in the context
      of hypertrophic cardiomyopathy, which supports the statement that beta-blockers
      are used to improve symptoms in this condition, though details on heart rate
      reduction specifically may be implied but not detailed.
  - reference: PMID:21389910
    supports: SUPPORT
    snippet: Throughout the years, numerous medical treatments have been used to achieve
      symptom control in these patients, and include medications such as beta-blockers,
      calcium channel blockers, amiodarone, disopyramide, and angiotensin receptor
      blockers.
    explanation: The abstract directly mentions the use of beta-blockers to control
      symptoms in hypertrophic cardiomyopathy, supporting the statement.
  - reference: PMID:37850394
    supports: SUPPORT
    snippet: beta-Adrenergic receptor antagonists (beta-blockers) are the first-line
      therapy for HCM. However, beta-blockers commonly selected for this disease are
      often poorly tolerated in patients, where heart-rate reduction and noncardiac
      effects can lead to reduced cardiac output and fatigue.
    explanation: This reference confirms that beta-blockers are a first-line therapy
      for hypertrophic cardiomyopathy and are used for heart rate reduction, supporting
      the statement.
  - reference: PMID:25198737
    supports: SUPPORT
    snippet: Beta-blocker therapy is without doubt the treatment of choice for patients
      with heart failure caused by hypertrophic cardiomyopathy, but the dose needs
      to carefully titrated on an individual basis for maximum benefit.
    explanation: The reference highlights the use of beta-blockers in hypertrophic
      cardiomyopathy to improve symptoms, aligning with the statement.
  treatment_term:
    preferred_term: beta adrenergic agent therapy
    term:
      id: MAXO:0000186
      label: beta adrenergic agent therapy
- name: Calcium Channel Blockers
  description: Help to relax heart muscle and improve blood flow
  evidence:
  - reference: PMID:17162264
    supports: SUPPORT
    snippet: For symptomatic patients with non-obstructed disease medical treatment
      with calcium channel blockers and beta-blockers is aimed to improve heart failure
      symptoms, and ischemia. Verapamil is the most often used, with likely benefit
      of relieving ischemia.
    explanation: The literature supports that calcium channel blockers are used to
      improve symptoms in hypertrophic cardiomyopathy patients, which implies relaxing
      the heart muscle and improving blood flow.
  - reference: PMID:3515244
    supports: SUPPORT
    snippet: The three approved calcium-channel blockers--nifedipine, verapamil and
      diltiazem--have offered new treatments for angina.
    explanation: Even though the focus is on angina, the acknowledged use of calcium
      channel blockers reinforces their role in cardiovascular conditions including
      HCM.
  - reference: PMID:36044874
    supports: SUPPORT
    snippet: CCBs are effective antihypertensive drugs and a very good therapeutic
      option for HTN LVH as they can cause reverse LVH remodeling.
    explanation: The review suggests the effectiveness of calcium channel blockers
      in treating hypertensive left ventricular hypertrophy (HTN LVH), indicating
      a role in remodeling heart muscle, which aligns with improving blood flow.
  - reference: PMID:7004293
    supports: SUPPORT
    snippet: The negative inotropic effects of verapamil are valuable in improving
      the symptoms and hemodynamic disturbances of hypertrophic cardiomyopathy.
    explanation: This directly supports the use of calcium channel blockers (specifically
      verapamil) in hypertrophic cardiomyopathy by improving symptoms and hemodynamics,
      which implies relaxing the heart muscle and improving blood flow.
  treatment_term:
    preferred_term: calcium channel blocking agent therapy
    term:
      id: MAXO:0000434
      label: calcium channel blocking agent therapy
- name: Septal Myectomy
  description: Surgical removal of part of the thickened heart muscle
  evidence:
  - reference: PMID:38368037
    supports: SUPPORT
    snippet: Septal myectomy is a well-established procedure for septal reduction
      in patients with obstructive hypertrophic cardiomyopathy (HCM) who have not
      responded to medical treatment.
    explanation: The literature directly confirms that septal myectomy is used to
      surgically remove part of the thickened heart muscle in hypertrophic cardiomyopathy
      patients.
  - reference: PMID:31280832
    supports: SUPPORT
    snippet: Surgical myectomy was initially advocated only for patients with symptoms
      refractory to maximal tolerated medical therapy.
    explanation: This supports the usage of septal myectomy for removing thickened
      muscle parts as a treatment for hypertrophic cardiomyopathy.
  - reference: PMID:22687587
    supports: SUPPORT
    snippet: Treatments for hypertrophic cardiomyopathy are largely selected based
      on patient symptoms and echocardiographic findings.
    explanation: While this reference does not directly state septal myectomy, it
      mentions treatment selection based on symptoms, which aligns with the usage
      context of septal myectomy in other literature. Therefore, it indirectly supports
      the use.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: Alcohol Septal Ablation
  description: Minimally invasive procedure to reduce obstruction by injecting alcohol
    into a small artery that supplies the thickened heart muscle
  evidence:
  - reference: PMID:35710280
    supports: SUPPORT
    snippet: Over the past several decades, alcohol septal ablation has become an
      established therapy for selected patients, in whom there is clinical improvement
      in symptoms as well as objective functional capacity.
    explanation: This reference supports the use of alcohol septal ablation as a treatment
      for hypertrophic cardiomyopathy by describing improved clinical outcomes and
      functional capacity.
  - reference: PMID:36598161
    supports: SUPPORT
    snippet: There are several invasive therapies including proven therapies such
      as alcohol septal ablation and septal myectomy.
    explanation: This reference supports the use of alcohol septal ablation as a proven
      therapy for hypertrophic cardiomyopathy.
  - reference: PMID:10980888
    supports: SUPPORT
    snippet: Following balloon inflation and intracoronary myocardial contrast echocardiography,
      ethyl alcohol is injected through the catheter lumen to cause proximal interventricular
      septum infarction and relief of outflow tract obstruction.
    explanation: This reference supports the description of alcohol septal ablation
      as a minimally invasive procedure to reduce obstruction by injecting alcohol.
  - reference: PMID:20973822
    supports: SUPPORT
    snippet: Alcohol septal ablation (ASA) has been shown to be an effective treatment
      in patients with hypertrophic obstructive cardiomyopathy (HOCM) who are refractory
      to medical treatment.
    explanation: This reference supports the effectiveness of alcohol septal ablation
      in treating hypertrophic cardiomyopathy by injecting alcohol into the septal
      artery.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: Implantable Cardioverter Defibrillator (ICD)
  description: Prevents sudden cardiac death in high-risk patients
  evidence:
  - reference: PMID:26002383
    supports: SUPPORT
    snippet: Nevertheless, several observational clinical studies have shown that
      the ICD reliably terminates life-threatening ventricular tachyarrhythmias in
      HCM, and is largely responsible for reducing HCM mortality to 0.5% per year,
      by preventing SD and changing the natural course of the disease.
    explanation: This excerpt supports the statement by showing that ICDs prevent
      sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy.
  - reference: PMID:36396186
    supports: SUPPORT
    snippet: Implantable cardioverter-defibrillators are the mainstay of therapy for
      prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy
      (HCM).
    explanation: This excerpt also supports the statement by confirming that ICDs
      are a primary treatment used to prevent sudden cardiac death in high-risk HCM
      patients.
  - reference: PMID:22687587
    supports: SUPPORT
    snippet: Risk of sudden death correlates with maximum left ventricular (LV) wall
      thickness. Massive LV thickening of 30 mm or more is an indication for primary
      prevention of sudden death with an implanted defibrillator.
    explanation: This excerpt provides specific criteria for using ICDs as a preventative
      measure in patients with significant hypertrophic cardiomyopathy, further supporting
      the statement.
  - reference: PMID:36134835
    supports: SUPPORT
    snippet: During follow-up of 4.8+/-3.4 years, there was no sudden cardiac death,
      but 20.6% patients with implantable cardioverter-defibrillator had at least
      one appropriate shock.
    explanation: While the focus is on the outcome of ICD shocks, the lack of sudden
      cardiac deaths among ICD patients aligns with the notion that ICDs prevent sudden
      cardiac death in high-risk HCM patients.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
disease_term:
  preferred_term: hypertrophic cardiomyopathy
  term:
    id: MONDO:0005045
    label: hypertrophic cardiomyopathy
classifications:
  harrisons_chapter:
    - classification_value: cardiovascular disorder
    - classification_value: cardiomyopathy
    - classification_value: hereditary disease
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Hypertrophic_Cardiomyopathy.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>